Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc. (NASDAQ: BYSI) generates a steady flow of news centered on the clinical and regulatory progress of its lead asset, Plinabulin, and on its corporate and financing activities. As a clinical-stage biopharmaceutical company focused on cancer, BeyondSpring’s updates often highlight new data from phase 2 and phase 3 trials in non-small cell lung cancer (NSCLC) and other tumor types, as well as mechanistic findings related to Plinabulin’s dendritic cell maturation and immune-modulating properties.
News releases frequently cover results from major oncology conferences and journals. Examples include presentations at the American Society of Clinical Oncology (ASCO), the IASLC/ASCO North America Conference on Lung Cancer (NACLC), the Society for Immunotherapy of Cancer (SITC), Immuno-Oncology 360°, and ESMO Asia, along with peer-reviewed publications in outlets such as Lancet Respiratory Medicine and Med (Cell Press). These communications describe outcomes from the DUBLIN‑3 phase 3 trial, the 303 and 302 phase 2 studies, and basket trials combining Plinabulin with checkpoint inhibitors, chemotherapy, and radiation.
Investors following BYSI news can also expect regular financial updates, including quarterly results, cash position, and operating expense trends, as well as 10‑K filing announcements. Corporate news items address equity financings, such as registered offerings of ordinary shares, and strategic transactions involving BeyondSpring’s equity stake in SEED Therapeutics, a targeted protein degradation company co-founded by BeyondSpring.
For market participants tracking oncology pipelines, the BYSI news stream provides insight into Plinabulin’s clinical performance, safety profile, biomarker research, and planned registrational strategies, including the company’s intention to advance confirmatory trials like DUBLIN‑4. Bookmarking the news page allows readers to monitor how new data, conference presentations, and SEC-referenced announcements may influence the development trajectory of Plinabulin and BeyondSpring’s broader strategy.
BeyondSpring (NASDAQ: BYSI) announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors, aiming to strengthen its oncology expertise as it seeks commercial approval for plinabulin. This follows promising Phase 3 data from the PROTECTIVE-2 study, which evaluates the drug's efficacy in preventing chemotherapy-induced neutropenia. Dr. Vacirca brings extensive experience as CEO of New York Cancer & Blood Specialists and is well-regarded in the oncology community, expected to enhance collaboration and strategic direction for BeyondSpring.
BeyondSpring (NASDAQ: BYSI) recently announced positive results from its Phase 3 PROTECTIVE-2 Study, showcasing that the combination of plinabulin and pegfilgrastim significantly reduces the incidence of profound neutropenia by 53% compared to pegfilgrastim alone (21.6% vs. 46.4%, p=0.0001). Additionally, the combination therapy leads to a 41% reduction in the odds of febrile neutropenia. These findings were presented at the 2020 San Antonio Breast Cancer Symposium. The company aims to submit a New Drug Application in Q1 2021, following Breakthrough Therapy Designation by the FDA.
BeyondSpring (NASDAQ: BYSI) announced its participation in two significant upcoming events: the 62nd American Society of Hematology (ASH) Annual Meeting (December 5-8, 2020) and the San Antonio Breast Cancer Symposium (SABCS) (December 8-11, 2020). Notably, the company will present findings from the PROTECTIVE-2 Trial, focusing on the Plinabulin and Pegfilgrastim combination's efficacy in preventing chemotherapy-induced neutropenia in breast cancer patients. Presentations will include a poster at ASH on December 5 and three posters at SABCS starting December 9, 2020, featuring research by Dr. Douglas W. Blayney from Stanford University.
BeyondSpring Inc. (NASDAQ: BYSI), a biopharmaceutical company focused on immuno-oncology therapies, will present a corporate overview at the Evercore ISI HealthCONx Conference on December 2, 2020. Dr. Lan Huang, Co-founder and CEO, will participate in a fireside chat at 9:15 am ET. Investors can access a live webcast and replay on BeyondSpring's website under the Investors section. The company's lead asset, plinabulin, is in a Phase 3 trial for non-small cell lung cancer and has received Breakthrough Therapy designation from the U.S. FDA for preventing chemotherapy-induced neutropenia.
BeyondSpring announced a public offering of 7,500,000 ordinary shares priced at $10.00 each, aiming to raise approximately $75 million. The offering is set to close on November 23, 2020, pending customary conditions. Proceeds will support the commercialization of plinabulin and further clinical development. The underwriters also hold a 30-day option for an additional 1,125,000 shares. The offering is conducted under the existing shelf registration with the SEC, effective from November 12, 2020.
BeyondSpring has launched an underwritten public offering of $75 million of its ordinary shares, with the potential to grant underwriters an additional $11.25 million. The proceeds are designated for the commercialization of Plinabulin, ongoing clinical development, and general corporate purposes. The offering is managed by BofA Securities, Jefferies, and Evercore ISI, with terms subject to market conditions. This offering follows the Company's effective shelf registration statement filed with the SEC on November 3, 2020.
BeyondSpring reported its Q3 2020 financial results and operational updates, highlighting a pivotal Phase 3 study for plinabulin showing superior outcomes in preventing chemotherapy-induced neutropenia compared to pegfilgrastim alone. The company plans to file a New Drug Application for plinabulin in the U.S. by early 2021.
Financially, R&D expenses rose to $8.6 million, while G&A expenses increased to $6.7 million, leading to a net loss of $14.5 million. BeyondSpring has $30.9 million in cash and believes it can sustain ongoing clinical trials and NDA preparations.
BeyondSpring (NASDAQ: BYSI) announced positive topline data from its PROTECTIVE-2 Phase 3 study, demonstrating that plinabulin combined with pegfilgrastim significantly prevents Grade 4 neutropenia in chemotherapy patients (31.5% vs. 13.6%, p=0.0015). The combination also achieved significant secondary endpoints, impacting duration of severe neutropenia and absolute neutrophil count. With Breakthrough Therapy designations from the U.S. FDA and China NMPA, BeyondSpring is preparing for NDA submission in Q1 2021. The study included 221 patients and provides promising insights for addressing chemotherapy-induced neutropenia in up to 440,000 U.S. patients annually.
BeyondSpring, a biopharmaceutical company trading on NASDAQ under the symbol BYSI, will present a corporate overview at the Jefferies London Healthcare Conference on November 17, 2020, at 2:55 pm Eastern Time. The event will highlight the company's innovative immuno-oncology therapies aimed at patients with high unmet medical needs. Plinabulin, their lead immune asset, is undergoing Phase 3 trials for chemotherapy-induced neutropenia and non-small cell lung cancer. The presentation can be accessed via a live webcast and archived on their official website.
Seed Therapeutics, a subsidiary of BeyondSpring, announced a collaboration with Eli Lilly to develop targeted protein degradation (TPD) therapies. The agreement includes a $10 million upfront payment and a $10 million equity investment from Lilly. Seed Therapeutics could receive up to $780 million in milestone payments and royalties from resulting products. The company aims to address previously undruggable proteins linked to diseases like cancer and Alzheimer's, utilizing its proprietary 'molecular glue' technology to create new therapeutic options.